Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
Apogee Therapeutics, Inc. will hold its 2026 virtual annual meeting on June 9, 2026 at 11:00 a.m. Eastern Time to vote on three proposals. Stockholders of record as of April 15, 2026, when 61,853,254 shares of voting common stock were outstanding, may participate.
Investors will elect three Class III directors to terms ending at the 2029 meeting, ratify Ernst & Young LLP as independent auditor for 2026, and cast a non-binding advisory vote on named executive officer pay. The board recommends voting “FOR” all proposals.
The proxy details Apogee’s classified board, supermajority voting for key charter and bylaw changes, and limits on stockholder special meetings and written consents. It highlights a pay-for-performance program in which 2025 bonuses paid at 130% of target, with CEO base salary at $700,000 and other named executives at $540,000.
Apogee Therapeutics, Inc. reported that two directors, Andrew Gottesdiener, M.D. and Peter Harwin, have notified the Board of their intention to resign effective May 11, 2026. The company states these resignations are not due to any disagreement regarding its operations, policies or practices.
Following their departure, the size of the Board will be reduced from nine directors to seven directors, consolidating governance among a smaller group of board members.
Apogee Therapeutics, Inc. Chief Executive Officer Michael Thomas Henderson exercised stock options to acquire 3,000 shares of common stock at $22.86 per share. Following this exercise, he directly holds 1,135,987 shares of common stock.
The exercised options are part of a grant representing the right to purchase 398,512 shares, which vests in forty-eight equal monthly installments over four years, subject to his continued service. After this transaction, 387,012 options from this grant remain outstanding and are scheduled to expire on December 18, 2033.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported an open-market sale of 2,000 shares of common stock at $90.00 per share on April 16, 2026. Following this transaction, she directly holds 175,371 shares of Apogee common stock.
According to a footnote, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 2, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson reported open-market sales of company common stock. On April 8, 2026, he sold 17,800 shares at a weighted average price of $82.48, 2,000 shares at $83.26, and 200 shares at $85.00.
These transactions were executed under a Rule 10b5-1 trading plan adopted on August 13, 2025, indicating they were pre-scheduled. Following these sales, Henderson directly holds 1,132,987 shares of Apogee Therapeutics common stock.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 10,291,220 shares of Apogee Therapeutics Inc. common stock, equal to 16.8% of the class as reported. The filing shows sole voting power over 9,762,311 shares and sole dispositive power over 10,291,220 shares. The T. Rowe Price Capital Appreciation Fund is disclosed with an interest of 5,295,932 shares (9.7%). The filing is signed and dated by an authorized officer.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski exercised stock options and sold shares in a planned transaction. He exercised options covering 4,125 shares of common stock at an exercise price of $22.86 per share and received 4,125 shares.
On the same date, he sold a total of 5,500 common shares in open-market trades at weighted average prices of about $84.31, $85.33, and $85.89, leaving him with 208,398 directly held shares. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025. A related option grant represents the right to purchase 175,345 shares vesting monthly through December 18, 2027, subject to continued service.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported routine open-market stock sales under a pre-arranged Rule 10b5-1 trading plan. On April 1, 2026, she sold 900 shares of common stock at a weighted average price of $84.46 and 1,100 shares at a weighted average price of $85.46, across multiple trades within disclosed price ranges. After these sales, she held 177,371 shares of common stock directly.
Apogee Therapeutics’ Chief Financial Officer Jane Henderson reported an open‑market sale of 2,000 shares of common stock at $85.00 per share. The transaction took place on March 25, 2026. After this sale, she directly holds 179,371 shares of Apogee common stock.
According to a footnote, this transaction was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 2, 2025. Such plans allow insiders to sell shares according to a preset schedule, reducing the role of day‑to‑day discretion in timing.